Search Results
Your search for early matches 10011 pages
Showing 251 - 300Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cameroon
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cameroon. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Impact of Prevention and Screening on Mortality From Five Common Cancers
Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published by Goddard et al in JAMA...
Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer
A novel cell-based immunotherapy may enhance treatment responses and reduce the need for conventional chemotherapy and its associated toxicities in patients with breast cancer, according to a recent study published by Han et al in JAMA Oncology. Study Methods and Results In the phase I clinical...
Self-Pay, AI-Based Program May Help Boost Mammogram Findings
A self-pay, artificial intelligence (AI)-enhanced breast cancer screening program could help improve breast cancer detection rates, according to new findings presented by Sorensen et al at the Radiological Society of North America (RSNA) 2024 Annual Meeting (Abstract R5B-SPBR-4). Background Despite ...
Cetuximab vs Durvalumab in Treatment of Head and Neck Cancers
Durvalumab, an immune checkpoint inhibitor, has shown activity in treating a wide range of cancers and has been proposed as a potentially safer and more effective option than cetuximab, according to Loren K. Mell, MD, Professor and Vice Chair of Clinical and Translational Research at University of ...
Deciphering the Impact of the 2024 Election on Cancer Care
Two weeks after the 2024 election, the Presidency and 119th Congress are coming into focus, with nearly all races called. Republican Donald Trump was elected President, and Republicans regained control of the U.S. Senate (53–47) and maintained control in the House of Representatives (218–212 at...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
Updated Findings in Preventive Breast Cancer Vaccine Study
Researchers from Cleveland Clinic recently presented updated findings from a novel study of a vaccine aimed at preventing triple-negative breast cancer. The findings were presented at the Society for Immunotherapy of Cancer Annual Meeting.1 According to researchers, including principal...
De-escalated Neoadjuvant Treatment Adding Nab-Paclitaxel or Docetaxel/Carboplatin to Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer
In a Chinese phase III trial (HELEN-006) reported in The Lancet Oncology, Chen et al found that the de-escalated neoadjuvant treatment with the addition of nab-paclitaxel to trastuzumab/pertuzumab produced a higher pathologic complete response rate (pCR) vs docetaxel/carboplatin plus...
Potential Cancer Vaccine Target Uncovered in E coli Bacteria
Targeting certain bacterial strains linked to cancer with treatments or vaccines may help to reduce the risk of colorectal cancer, urothelial carcinoma, and prostate cancer, according to a novel study published by Mäklin et al in The Lancet Microbiome. Background The bacterium Escherichia coli is...
Prophylactic Surgical Menopause for Women With Familial Risk of Ovarian Cancer: Impact on Coronary Artery Calcium Development
The results of the HARMOny study published in JACC: CardioOncology by Beekman et al did not reveal a long-term adverse effect of prophylactic surgical menopause on the development of coronary artery calcium—a marker of cardiovascular disease risk—in women with a high familial risk of ovarian...
Study Evaluating Lung Cancer Screening Program Receives Margulis Award for Scientific Excellence
The 2024 Alexander R. Margulis Award for Scientific Excellence honored the authors of a 20-year follow-up study on the International Early Lung Cancer Action Program (I-ELCAP). The Margulis Award was presented recently during the 2024 Radiological Society of North America (RSNA) Scientific Assembly ...
Understanding the Link Between Obesity and Cancer
Worldwide, more than a billion people have obesity—including 650 million adults, 340 million adolescents, and 39 million children1—a rate that has nearly doubled since 1980.2 In the United States alone, about two out of three adults are overweight or have obesity, and one out of three have...
Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit
Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data presented at the European Society for Medical Oncology (ESMO) Congress 20241 and published...
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a...
Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin
As reported in The Lancet Oncology by Mell et al, the phase II/III NRG-HN004 trial of radiotherapy with durvalumab or cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma and contraindications for cisplatin was stopped for futility during phase II; the phase III...
Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology. Dr. Ürün is Professor of Medicine at the Ankara University School of Medicine in Turkey. After...
At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates
Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...
Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1–Associated Plexiform Neurofibroma
In a phase IIb trial (ReNeu) reported in the Journal of Clinical Oncology, Moertel et al found that the CNS-penetrant small molecule MEK1/2 inhibitor mirdametinib showed activity in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma (NF1-PN). Study...
Nodal Burden and Recurrence in Patients With Breast Cancer With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy
In a retrospective study (OPBC-05/ICARO) reported in the Journal of Clinical Oncology, Giacomo Montagna, MD, MPH, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that nodal burden in patients with breast cancer with residual isolated tumor cells after neoadjuvant...
KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-naive, unresectable, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.1...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
T-DXd of Benefit in Patients With Breast Cancer and Brain Metastases
Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least...
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and ‘all-negative’ subtypes.1...
Highlights From the ESMO Congress 2024
The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...
Cancer Has Plagued My Family
My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
In earlier issues of The ASCO Post, we shared unique insights from recipients of the International Development and Education Award (IDEA), whose experiences at the 2024 ASCO Annual Meeting (ASCO24) had a profound impact on their professional and personal growth. Here are more reflections from...
High Burden of Chronic Health Conditions, Disability, and Cognitive and Physical Limitations Reported in LGBTQ+ Cancer Survivors
Although improvements in the early detection and treatment of cancer have reduced cancer-related mortality rates and increased the number of cancer survivors in the United States to more than 18 million,1 not all patients with the disease are benefiting from these advances. Austin R. Waters, MSPH,...
Impact of Food Insecurity on the Incidence of Hepatocellular Carcinoma
At the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Rebecca D. Kehm, PhD, of Columbia University Mailman School of Public Health, New York, and colleagues presented some of the ...
Katherine Van Loon Named Editor-in-Chief of JCO Global Oncology
Katherine Van Loon, MD, MPH, has been appointed as the next Editor-in-Chief of JCO Global Oncology (JCO GO). JCO GO is an online-only, open-access ASCO journal focusing on cancer research, care, and delivery in low-resource countries and settings. The journal aims to address the challenges faced...
Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor
The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier...
Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer
Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...
Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma
Hai-Qiang Mai, MD, of the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues reported their findings from a single-center phase II trial in The Lancet Oncology.1 They found that the addition of perioperative toripalimab to concurrent...
Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists
Participants of the American Society of Hematology (ASH) Minority Recruitment Initiative had lower attrition rates in graduate and medical programs, were more likely to pursue a career in hematology, and had high levels of engagement at ASH beyond their participation in the program, according to a ...
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
Georgina V. Long, PhD, MBBS, FRACP, of Melanoma Institute Australia and Royal North Shore and Mater Hospitals, The University of Sydney, and colleagues shared their findings from a pooled analysis of long-term outcomes in advanced melanoma reported in the Journal of Clinical Oncology.1 They found...
Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?
Question: Based on NATALEE and monarchE data, is there still a need for neoadjuvant chemotherapy in hormone receptor (HR)-positive, HER2-negative early breast cancer? Answer: In monarchE trial, the CDK4/6 inhibitor abemaciclib combined with endocrine therapy demonstrated long-term efficacy in...
Increase in Young-Onset Pancreatic Cancer May Be Due to Overdiagnosis of Early-Stage Endocrine Cancer
A recent analysis of pancreatic cancer data in young adults (aged 15–39) has found that although there is an increase in incidence, the mortality rate remains stable. According to Patel et al, who published their findings in the Annals of Internal Medicine, the rise in incidence is primarily due to ...
Novel Liquid Biopsies and Cancer Detection
Researchers may have uncovered a novel strategy to detect cancer cells with a liquid biopsy that’s designed to be simpler, faster, and more informational than current methods, according to a recent study published by Walker et al in the nanoscience publication Small. Study Methods and Results In...
Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?
Just 50% of patients with early-onset cancers may report discussing fertility preservation options with their physicians prior to receiving oncology treatments, according to a recent study published by Keller et al in JAMA Network Open. Background “From an early-onset cancer diagnosis through to...
Exploring Issues in Oncofertility
“Cancer in young adults is more complicated in part [because of the risk of] infertility and premature menopause,” commented Ann H. Partridge, MD, MPH, FASCO, Interim Chair, Department of Medical Oncology; the Eric P. Winer, MD Chair in Breast Cancer Research, Dana-Farber Cancer Institute; and ...
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In a prospective analysis reported in JAMA Network Open, Patel et al found that long-term health-related quality of life (HRQOL) was poorer among patients with prostate cancer who received postprostatectomy radiotherapy vs those who did not, with little difference observed among patients with early ...
Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer
As reported in the Journal of Clinical Oncology by Jensen et al, the final analysis of the phase III Danish DBCG07-READ trial showed improved 10-year outcomes with the addition of epirubicin to docetaxel/cyclophosphamide adjuvant therapy in patients with TOP2A-normal breast cancer. The primary...
Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers
Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine....
Effect of Smoking Cessation Intervention on Survival After a Cancer Diagnosis
In a single-institution study reported in JAMA Oncology, Cinciripini et al found that patients with cancer who quit smoking after a smoking cessation intervention had improved overall survival after cancer diagnosis. Study Details and Results The study involved data on 4,526 patients who were...
Breast Cancer Vaccine Could Be Preventive, Well Tolerated in High-Risk Patients
Researchers have uncovered insights into a novel investigational vaccine aimed at preventing triple-negative breast cancer. The findings by Rhoades et al were presented at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting (Abstract 631) and simultaneously published in the Journal...
TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
